Clinical aspects of exhaled nitric oxide

European Respiratory Journal

Volumn 16, Issue 4, 2000, Pages 781-792

  Kharitonov, S A ^a   Barnes, P J ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Asthma; Exhaled breath; Inflammation; Isoprostanes; Nitric oxide; Noninvasive markers of airway; S nitrosothiols

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; DEXAMETHASONE; FLUNISOLIDE; FLUTICASONE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; NITRIC OXIDE; PRANLUKAST; PREDNISOLONE; SALBUTAMOL;

ARTICLE; ASTHMA; BRONCHIECTASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CILIARY DYSKINESIA; CORRELATION FUNCTION; CORTICOSTEROID THERAPY; CYSTIC FIBROSIS; HUMAN; INFLAMMATORY DISEASE; PATHOPHYSIOLOGY; PATIENT MONITORING; PRIORITY JOURNAL; SKIN TEST;

EID: 0033768818     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.00.16478100     Document Type: Article

References (143)

1. Induced sputum, eosinophilic bronchitis, and chronic obstructive pulmonary disease
2. Effect of repeated sputum induction on cell counts in normal volunteers
3. Changes in sputum composition between two inductions performed on consecutive days
4. The elevated level of exhaled nitric oxide in asthmatic patients is mainly derived from the lower respiratory tract
5. Increased formation of the potent oxidant peroxynitrite in the airways of asthmatic patients is associated with induction of nitric oxide synthase: Effect of inhaled glucocorticoid
6. Correlation between exhaled nitric oxide, sputum eosinophils, and methacholine responsiveness in patients with mild asthma
7. Detection of inducible NO-synthase (iNOS) in sputum cells of healthy and asthmatic subjects
8. Methods for sputum induction and analysis of induced sputum: A method for assessing airway inflammation in asthma
9. 2-agonists on exhaled nitric oxide in asthmatic patients
10. Corticosteroids decrease exhaled nitric oxide in children with acute asthma
11. Effect of salmeterol treatment on nitric oxide level in exhaled air and dose-response to terbutaline in children with mild asthma
12. Induction of nitric oxide synthase in asthma
13. Nitric oxide and asthmatic inflammation
14. Increased nitric oxide in exhaled air of asthmatic patients
15. Exhaled nitric oxide (NO), NO synthase activity, and regulation of nuclear factor (NF)-kappaB
16. Increased amount of nitric oxide in exhaled air of asthmatics
17. Changes in the dose of inhaled steroid affect exhaled nitric oxide levels in asthmatic patients
18. Inhaled glucocorticoids decrease nitric oxide in exhaled air of asthmatic patients
19. Exhaled NO is elevated in difficult asthma and correlates with symptoms and disease severity despite treatment with oral and inhaled corticosteroids
20. Comparison of exhaled nitric oxide, serum eosinophilic cationic protein, and soluble interleukin-2 receptor in exacerbations of pediatric asthma
21. Comparison of exhaled nitric oxide to spirometry during emergency treatment of asthma exacerbations with glucocorticosteroids in children
22. Nitric oxide is present in exhaled breath in humans: Direct GC-MS confirmation
23. Exhaled and nasal nitric oxide measurements: Recommendations
24. Recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide in adults and children
25. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor
26. Expression of inducible nitric oxide synthase and formation of peroxynitrite in post-transplant obliterative bronchiolitis
27. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension
28. Immunohistochemical localization of nitric oxide synthase and the oxidant peroxynitrite in lung transplant recipients with obliterative bronchiolitis
29. Elevated nitric oxide concentrations in isolated lower airway gas of asthmatic subjects
30. Primarily nasal origin of exhaled nitric oxide and absence in Kartagener's syndrome
31. Marked flow-dependence of exhaled nitric oxide using a new technique to exclude nasal nitric oxide
32. In stable lung transplant recipients, exhaled nitric oxide levels positively correlate with airway neutrophilia and bronchial epithelial iNOS
33. Effect of a nitric oxide synthase inhibitor and a glucocorticosteroid on exhaled nitric oxide
34. Endogenous nitric oxide is decreased in asthmatic patients by an inhibitor of inducible nitric oxide synthase
35. Effect of nitric oxide synthesis inhibition with nebulized L-NAME on ventilation-perfusion distributions in bronchial asthma
36. Exhaled nitric oxide does not provide a marker of vascular endothelial function in healthy humans
37. Effect of inhaled budesonide on lung function and airway inflammation
38. Effect of differing doses of inhaled budesonide on markers of airway inflammation in patients with mild asthma
39. Time course of change in bronchial reactivity with an inhaled corticosteroid in asthma
40. Administration of budesonide once daily by means of turbuhaler to subjects with stable asthma
41. Childhood asthma: Exhaled nitric oxide in relation to clinical symptoms
42. Effect of sputum induction on spirometric measurements and arterial oxygen saturation in asthmatic patients, smokers, and healthy subjects
43. Changes in sputum composition during sputum induction in healthy and asthmatic subjects
44. A dose-dependent effect of the novel inhaled corticosteroid ciclesonide on airway responsiveness to adenosine-5'monophosphate in asthmatic patients
45. Fractional analysis of sequential induced sputum samples during sputum induction: Evidence that different lung compartments are sampled at different time points
46. Neutrophilic inflammation in severe persistent asthma
47. Eosinophilic inflammation assessed by induced sputum in corticosteroid-dependent asthma
48. Expired nitric oxide levels during treatment of acute asthma
49. Exhaled and nasal nitric oxide is increased in laboratory animal allergy
50. Exhaled nitric oxide and bronchial hyperreactivity in atopic and non-atopic patients
51. Relationship between exhaled nitric oxide and childhood asthma
52. Inhaled flunisolide can prevent an increase in exhaled nitric oxide levels in allergic asthmatic children exposed to relevant allergens
53. Allergen-induced late asthmatic reactions are associated with elevation of exhaled nitric oxide
54. Effect of natural grass pollen exposure on exhaled nitric oxide in asthmatic children
55. Exhaled nitric oxide, sensitization, and exposure to allergens in patients with asthma who are not taking inhaled steroids
56. Exhaled and nasal NO levels in allergic rhinitis: Relation to sensitization, pollen season, and bronchial hyperresponsiveness
57. Allergen avoidance is associated with a fall in exhaled nitric oxide in asthmatic children
58. The influence of atopy on exhaled nitric oxide in patients with asthma and/or rhinitis
59. Exhaled nitric oxide, bronchial hyperreactivity and airways obstruction in asthmatics and nonasthmatics subjects
60. Exhaled nitric oxide in asthmatics correlates with atopy and bronchial reactivity but not with steroids use or clinical control
61. Sensitization, and exposure to allergens in patients with asthma who are not taking inhaled steroids
62. Orally exhaled nitric oxide levels are related to the degree of blood eosinophilia in atopic children with mild-intermitten asthma
63. Exhaled nitric oxide as a noninvasive assessment of chronic cough
64. Exhaled nitric oxide correlates with airway hyperresponsiveness in steroid-naive patients with mild asthma
65. Sputum cell counts and exhaled nitric oxide in patients with nonasthmatic cough and gastro-esophageal reflux
66. Expired nitric oxide levels during treatment of acute asthma
67. Exhaled nitric oxide concentrations during treatment of wheezing exacerbation in infants and young children
68. An inhaled steroid improves markers of airway inflammation in patients with mild asthma
69. Effect of inhaled steroids on airway hyperresponsiveness, sputum eosinophils, and exhaled nitric oxide levels in patients with asthma
70. Lack of inhibitory effect of dexamethasone on exhalation of nitric oxide by healthy humans
71. Interleukin-4 receptor in moderate atopic asthma. A phase i/ii randomized, placebo-controlled trial
72. Reduction in exhaled nitric oxide after a single dose of nebulized budesonide in patients with asthma
73. Exhaled nitric oxide and bronchial reactivity dyring and after inhaled beclomethasone in mild asthma
74. Dose-dependent onset and duration of action of 100/400 mcg budesonide on exhaled nitric oxide and related changes in other potential markers of airway inflammation in mild asthma
75. Dexamethasone increases survival and attenuates induction of inducible nitric oxide synthase in experimental skin flaps
76. Eosinophils transcribe and translate messenger RNA for inducible nitric oxide synthase
77. Functional assay of NF-kappaB translocation into nuclei by laser scanning cytometry: Inhibitory effect by dexamethasone or theophylline
78. Exhaled nitric oxide during acute changes of airways calibre in asthma
79. Decreased exhaled nitric oxide in mild persistent asthma patients treated with a leukotriene receptor antagonist, pranlukast
80. NO in exhaled air of asthmatic children is reduced by the leukotriene receptor antagonist montelukast
81. Exhaled nitric oxide before and after montelukast sodium therapy in school-age children with chronic asthma: A preliminary study
82. 2 and F(2α) reduce exhaled nitric oxide in normal and asthmatic subjects irrespective of airway calibre changes
83. Prostaglandins mediate bradykinin-induced reduction of exhaled nitric oxide in asthma
84. 2 antagonist on airway hyperresponsiveness, exhaled nitric oxide, and induced sputum eosinophils in asthmatics
85. Exhaled nitric oxide is not elevated in the inflammatory airways diseases of cystic fibrosis and bronchiectasis
86. Exhaled NO in pediatric asthma and cystic fibrosis
87. Decreased concentration of exhaled nitric oxide (NO) in patients with cystic fibrosis
88. Airway nitric oxide in asthmatic children and patients with cystic fibrosis
89. Exhaled nitric oxide in paediatric asthma and cystic fibrosis
90. Reduced upper airway nitric oxide in cystic fibrosis
91. Inducible nitric oxide synthase expression is reduced in cystic fibrosis murine and human airway epithelial cells
92. Lack of inducible nitric oxide synthase in bronchial epithelium: A possible mechanism of susceptibility to infection in cystic fibrosis
93. Nitric oxide-mediated regulation of transepithelial sodium and chloride transport in murine nasal epithelium
94. Lower airway inflammation in infants and young children with cystic fibrosis
95. Pulmonary oxidative stress response in young children with cystic fibrosis
96. Superoxide causes a reduction in nitric oxide gas and an increase in nitrate
97. Neutrophil-derived long-lived oxidants in cystic fibrosis sputum
98. Total sputum nitrate plus nitrite is raised during acute pulmonary infection in cystic fibrosis
99. Evidence for increased oxidative damage in patients with cystic fibrosis
100. Pulmonary dysfunction in cystic fibrosis is associated with oxidative stress
101. Oxidative damage to DNA in patients with cystic fibrosis
102. Measurement of exhaled nitric oxide by three different techniques
103. Nitric oxide inhalation during exercise in chronic obstructive pulmonary disease
104. Role of endogenous nitric oxide in airflow obstruction in smokers
105. Increased levels of exhaled nitric oxide in smoking subjects with stable chronic obstructive pulmonary disease and in patients with COPD exacerbation
106. Acute and chronic effects of cigarette smoking on exhaled nitric oxide
107. Increased nitric oxide in exhaled air of patients with stable chronic obstructive pulmonary disease
108. Nasal nitric oxide and its relationship to nasal symptoms, smoking and nasal nitrate
109. Effect of cigarette smoke extract on nitric oxide synthase in pulmonary artery endothelial cells
110. Smoking cessation is associated with an increase in exhaled nitric oxide
111. Plasma 3-nitrotyrosine in cigarette smokers
112. Formation of 8-nitroguanine in DNA treated with peroxynitrite in vitro and its rapid removal from DNA by depurination
113. Exhaled nitric oxide in chronic obstructive pulmonary disease
114. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma
115. Structural and inflammatory changes in COPD: A comparison with asthma
116. Markers of nitric oxide metabolism in sputum and exhaled air are not increased in chronic obstructive pulmonary disease
117. Mechanisms of damage in COPD
118. Exhaled nitric oxide levels in patients with chronic obstructive pulmonary disease
119. Acidosis stimulates nitric oxide production and lung damage in rats
120. The chemistry of peroxymitrite: A product from the reaction of nitric oxide with superoxide
121. Effect of L-arginine on mucociliary function in primary ciliary dyskinesia
122. Elevated levels of exhaled nitric oxide in bronchiectasis
123. L-arginine increases exhaled nitric oxide in normal human subjects
124. The use of exhaled nitric oxide levels as a screening tool in respiratory disease states
125. Decreased nitric oxide in the exhaled air of systemic sclerosis patients with pulmonary hypertension
126. Endothelial nitric oxide synthase in hypoxic newborn porcine pulmonary vessels
127. Nitric oxide and endothelin-1 in pulmonary hypertension
128. Chronic EDRF inhibition and hypoxia: Effects on pulmonary circulation and systemic blood pressure
129. Endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension
130. Increased endothelial NOS in lambs with increased pulmonary blood flow and pulmonary hypertension
131. Variable expression of endothelial NO synthase in three forms of rat pulmonary hypertension
132. eNOS expression is not altered in pulmonary vascular remodeling due to increased pulmonary blood flow
133. High expression of endothelial nitric oxide synthase in plexiform lesions of pulmonary hypertension
134. Exhaled nitric oxide during exercise in primary pulmonary hypertension and pulmonary fibrosis
135. Decreased exhaled nitric oxide may be a marker of cardiopulmonary bypass-induced injury
136. Exhaled nitric oxide is increased in active fibrosing alveolitis
137. Exhaled nitric oxide and bronchoalveolar lavage nitrite/nitrate in active pulmonary sarcoidosis
138. Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Adjunctive therapy to maintenance immunosuppression
139. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group
140. Induced sputum eicosanoid concentrations in asthma
141. Nitrotyrosine and cystenyl leukotrienes in breath condensates are increased after withdrawal of steroid treatment in patients with asthma
142. Increased 8-isoprostane, a marker of oxidative stress, in exhaled condensate of asthma patients
143. Breath condensate analysis of 8-isoprostane: A new approach for assessment of oxidative stress in patients with chronic obstructive pulmonary disease